This Brief reviews a potential treatment option for patients with ulcerative colitis. This chronic inflammatory disease may significantly affect a person’s health and quality of life. A once-daily oral medication, MMX mesalamine, may be beneficial to these patients by limiting pill burden and potentially increasingly the likelihood of medication compliance.
Discussion of the incidence and prevalence of ulcerative colitis, along with its socioeconomic impact
Overview of the available treatment modalities, with a focus on 5-aminosalicylate therapy
Review of two pivotal trials that examined the efficacy of MMX mesalamine for patients with mild-to-moderative ulcerative colitis